In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/teclistamab-alone-ups-previously-treated-myeloma-survival-2026a1000i2u?src=rss
Author :
Publish date : 2026-05-31 21:55:00
Copyright for syndicated content belongs to the linked Source.